Tirzepatide linked to 35% lower glaucoma risk than GLP-1RAs in Type 2 Diabetes patients
Background
Type 2 Diabetes Mellitus (T2DM) patients face an elevated risk of various microvascular complications, including ocular conditions like glaucoma. While glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized T2DM and obesity management, recent retrospective studies have raised concerns regarding their potential association with increased risks of diabetic retinopathy and nonarteritic anterior ischemic optic neuropathy (NAION). Given these emerging ocular safety signals for GLP-1RAs, there's a critical need to understand the comparative ocular safety profile of newer dual agonists like tirzepatide, which targets both GLP-1R and GIPR, especially concerning primary open-angle glaucoma (POAG).
Study Design
This retrospective cohort study utilized a large, multinational, deidentified database to compare the risk of incident POAG. Participants included 51,540 adults aged ≥60 years with T2DM who were newly prescribed either tirzepatide or a GLP-1RA between 2022 and 2024. The two groups were meticulously balanced using 1:1 propensity score matching based on numerous covariates including age, sex, race, smoking history, glycated hemoglobin, BMI, and prior medication use. The primary endpoint was incident POAG over a 2-year follow-up period.
Results
A total of 51,540 participants were included in the final analysis after propensity score matching. Compared to GLP-1RAs, tirzepatide was significantly associated with a lower risk of incident POAG over the 2-year follow-up period. The observed hazard ratio (HR) was 0.65 (95% confidence interval, 0.44-0.96), indicating a 35% reduction in risk. This primary finding was robust and remained consistent across multiple sensitivity analyses. These included analyses excluding individuals with early POAG events after the index date, restricting the cohort to patients with ≥1 subsequent prescription, an intention-to-treat design, and limiting the analysis exclusively to individuals with an ophthalmology visit. This consistency across varied analytical approaches strengthens the reliability of the association.
Tirzepatide was associated with a 35% lower risk of primary open-angle glaucoma (HR, 0.65; 95% CI, 0.44-0.96) compared to GLP-1RAs in T2DM patients.
Key Findings
- Tirzepatide was associated with a 35% lower risk of incident primary open-angle glaucoma (POAG) compared to GLP-1RAs.
- The hazard ratio for POAG with tirzepatide vs. GLP-1RAs was 0.65 (95% CI, 0.44-0.96).
- The analysis included 51,540 adults aged ≥60 years with Type 2 Diabetes.
- Findings remained consistent across multiple sensitivity analyses, strengthening the association.
Why It Matters
This finding suggests a potential ocular safety advantage for tirzepatide over traditional GLP-1RAs concerning glaucoma risk in T2DM patients. Given the prior concerns about GLP-1RAs and other ocular complications, this comparative data is crucial for clinical decision-making. Clinicians may consider tirzepatide as a preferred option for T2DM patients, particularly those with existing glaucoma risk factors or a history of ocular complications, to potentially mitigate glaucoma progression. While this study does not alter existing dosing protocols, it provides valuable insights for personalized medicine, guiding the choice between GLP-1RAs and dual agonists like tirzepatide based on a patient's overall risk profile, including ocular health. Further research is needed to elucidate the underlying mechanisms of this differential effect.
tirzepatide
glp-1ra
type-2-diabetes
glaucoma
poag
retrospective-cohort